{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04701476",
            "orgStudyIdInfo": {
                "id": "LT-007"
            },
            "secondaryIdInfos": [
                {
                    "id": "KEYNOTE-A91",
                    "type": "OTHER",
                    "domain": "Merck & Co."
                }
            ],
            "organization": {
                "fullName": "Teclison Ltd.",
                "class": "INDUSTRY"
            },
            "briefTitle": "TATE and Pembrolizumab (MK3475) in mCRC and NSCLC",
            "officialTitle": "An Open Label Phase II Study for the Treatment of Liver Metastatic Colorectal Cancer and Non-Small Cell Lung Cancer With a Combination of TATE (Trans-Arterial Tirapazamine Embolization) and Pembrolizumab",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "tate-and-pembrolizumab-in-mcrc-and-nsclc"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-09",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-05-20",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-10-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-01-06",
            "studyFirstSubmitQcDate": "2021-01-07",
            "studyFirstPostDateStruct": {
                "date": "2021-01-08",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-09-18",
            "lastUpdatePostDateStruct": {
                "date": "2023-09-21",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Teclison Ltd.",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "Merck Sharp & Dohme LLC",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.",
            "detailedDescription": "This study is an open-label study to treat patients with refractory metastatic colorectal cancer and non-small cell lung cancer with liver metastasis. Patients enrolled in the mCRC cohort will be randomized to receive study treatment Trans-arterial Tirapazamine Embolization (TATE)+Pembrolizumab or FDA-approved standard of care, such as TAS-102 or regorafenib, and their Overall Survival (OS) will be compared in the two cohorts as the primary endpoint. Patients enrolled in the NSCLC cohort will all receive study treatment TATE+Pembrolizaumb and Overall Response Rate (ORR) will be the primary endpoint."
        },
        "conditionsModule": {
            "conditions": [
                "Colorectal Cancer; Lung Cancer"
            ],
            "keywords": [
                "colorectal cancer",
                "NSCLC",
                "pembrolizumab",
                "tirapazamine",
                "Liver metastasis"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "Open-label study in two indications. The mCRC cohort will be a randomized trial for TATE+Pembrolizumab versus standard 3rd line therapy for mCRC. The NSCLC cohort will be single-arm study.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 110,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "colorectal cancer",
                    "type": "EXPERIMENTAL",
                    "description": "metastatic colorectal cancer progressed on at least two lines of chemotherapy",
                    "interventionNames": [
                        "Drug: TATE and pembrolizumab",
                        "Drug: TAS-102 pill",
                        "Drug: Regorafenib Pill"
                    ]
                },
                {
                    "label": "NSCLC",
                    "type": "EXPERIMENTAL",
                    "description": "Liver metastatic NSCLC progressed on immune checkpoint inhibitors and chemotherapy",
                    "interventionNames": [
                        "Drug: TATE and pembrolizumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "TATE and pembrolizumab",
                    "description": "All liver metastatic lesions will be treated with TATE for maximally debulking. Pembrolizumab IV infusion per standard schedule every 3 or 6 weeks until progression or maximally 2 years.",
                    "armGroupLabels": [
                        "NSCLC",
                        "colorectal cancer"
                    ],
                    "otherNames": [
                        "TATE: Trans-arterial Tirapazamine Embolization;"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "TAS-102 pill",
                    "description": "The comparator of the mCRC arm is TAS-102 at 60 mg BID 5 days per week for 2 weeks then 2 weeks off.",
                    "armGroupLabels": [
                        "colorectal cancer"
                    ],
                    "otherNames": [
                        "LONSURF"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Regorafenib Pill",
                    "description": "As an alternative to TAS-102 per treating physician's discretion. If selected, Regorafenib 160 mg oral daily for 3 weeks on and one week off, every 4 weeks per cycle. Do not take Regoarefnib if taking TAS-102.",
                    "armGroupLabels": [
                        "colorectal cancer"
                    ],
                    "otherNames": [
                        "STIVARGA"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Overall Survival for the mCRC cohort",
                    "description": "From the first day of treatment to death",
                    "timeFrame": "24 months"
                },
                {
                    "measure": "Overall Response Rate (ORR) for the NSCLC cohort",
                    "description": "Per RECIST 1.1 criteria",
                    "timeFrame": "within 24 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Duration of Response",
                    "description": "per RECIST 1.1",
                    "timeFrame": "24 months"
                },
                {
                    "measure": "Response rate",
                    "description": "in TATE treated or TATE-untreated lesions by RECIST and mRECIST",
                    "timeFrame": "24 months"
                },
                {
                    "measure": "PFS",
                    "description": "Progression Free Survival",
                    "timeFrame": "24 months"
                },
                {
                    "measure": "TTP",
                    "description": "Time to Progression",
                    "timeFrame": "24 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Liver metastatic MSS-mCRC or NSCLC without EGFR or AKT mutations\n* mCRC progressed on at least two lines of standard chemotherapy; or\n* NSCLC progressed on chemotherapy and an immune checkpoint inhibitor\n* Measurable disease\n* ECOG 0-1\n* At least 4 weeks from prior chemotherapy and free from chemo-related toxicity\n* Adequate organ function\n\nExclusion Criteria:\n\n* Prior organ transplantation\n* Liver metastasis more than 50%\n* Oxygen saturation less than 92% in room air\n* Prior autoimmune disorder\n* CNS metastasis\n* Major GI bleeding in the last 2 months",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Ray Lee, MD. PhD.",
                    "role": "CONTACT",
                    "phone": "8043341076",
                    "email": "ray.lee01@teclison.com"
                },
                {
                    "name": "Chiwei Lu",
                    "role": "CONTACT",
                    "email": "chiwei.lu4@teclison.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Ray Lee",
                    "affiliation": "Teclison Limited",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of California, Irvine Medical Center",
                    "status": "RECRUITING",
                    "city": "Orange",
                    "state": "California",
                    "zip": "92868",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Miranda Duron",
                            "role": "CONTACT",
                            "email": "mnduron@hs.uci.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.78779,
                        "lon": -117.85311
                    }
                },
                {
                    "facility": "China Medical University Hsinchu Hospital",
                    "status": "RECRUITING",
                    "city": "Hsinchu",
                    "country": "Taiwan",
                    "contacts": [
                        {
                            "name": "sandy Lai",
                            "role": "CONTACT",
                            "email": "sandy6618@teclison.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 24.80361,
                        "lon": 120.96861
                    }
                },
                {
                    "facility": "Chung Shan Medical University Hospital",
                    "status": "RECRUITING",
                    "city": "Taichung",
                    "country": "Taiwan",
                    "contacts": [
                        {
                            "name": "Sandy Lai",
                            "role": "CONTACT",
                            "email": "sandy6618@teclison.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 24.1469,
                        "lon": 120.6839
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO",
            "description": "International meeting report or medical Journal publication"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008175",
                    "term": "Lung Neoplasms"
                },
                {
                    "id": "D000015179",
                    "term": "Colorectal Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000012142",
                    "term": "Respiratory Tract Neoplasms"
                },
                {
                    "id": "D000013899",
                    "term": "Thoracic Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000008171",
                    "term": "Lung Diseases"
                },
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                },
                {
                    "id": "D000007414",
                    "term": "Intestinal Neoplasms"
                },
                {
                    "id": "D000005770",
                    "term": "Gastrointestinal Neoplasms"
                },
                {
                    "id": "D000004067",
                    "term": "Digestive System Neoplasms"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                },
                {
                    "id": "D000005767",
                    "term": "Gastrointestinal Diseases"
                },
                {
                    "id": "D000003108",
                    "term": "Colonic Diseases"
                },
                {
                    "id": "D000007410",
                    "term": "Intestinal Diseases"
                },
                {
                    "id": "D000012002",
                    "term": "Rectal Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5546",
                    "name": "Carcinoma, Non-Small-Cell Lung",
                    "relevance": "LOW"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "asFound": "Lung Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12307",
                    "name": "Neoplasm Metastasis",
                    "relevance": "LOW"
                },
                {
                    "id": "M17890",
                    "name": "Colorectal Neoplasms",
                    "asFound": "Colorectal Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14979",
                    "name": "Respiratory Tract Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M16658",
                    "name": "Thoracic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11168",
                    "name": "Lung Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10448",
                    "name": "Intestinal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7256",
                    "name": "Digestive System Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M8886",
                    "name": "Gastrointestinal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M6336",
                    "name": "Colonic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10444",
                    "name": "Intestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14844",
                    "name": "Rectal Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000582435",
                    "term": "Pembrolizumab"
                },
                {
                    "id": "D000077704",
                    "term": "Tirapazamine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M349416",
                    "name": "Pembrolizumab",
                    "asFound": "Mg/m2",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M11110",
                    "name": "Liver Extracts",
                    "relevance": "LOW"
                },
                {
                    "id": "M1875",
                    "name": "Tirapazamine",
                    "asFound": "Prior Chemotherapy",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Hemat",
                    "name": "Hematinics"
                }
            ]
        }
    },
    "hasResults": false
}